Abstract: The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Abstract: The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Abstract: The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

Abstract: The present disclosure provides a compound. The compound is a compound shown in formula (1) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug of the compound shown in formula (1). The compound shown in formula (1) can significantly inhibit Mpro or inhibit coronavirus replication, and has excellent metabolic stability.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules as defined within Formula I (as defined herein) which function as inhibitors of glucose-regulated protein 78 (GRP78) within cancer cells and/or immune cells, and which function as effective therapeutic agents for treating, ameliorating, and preventing various forms of cancer (e.g., pancreatic cancer), viral infections (e.g. SARS-CoV-2), and inflammatory diseases. In addition, this invention also relates to a new class of PROTACs having Formulas II, III and IV (as defined herein) which function as degraders of GRP78 within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds of Formulas I, II, III, or IV are also within the scope of the present invention.

Abstract: The present disclosure provides a compound. The compound is a compound as shown in Formula (I) or a stereoisomer, tautomer, deuterated compound, oxynitride, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound having a structure as shown in Formula (I).

Abstract: The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.

Abstract: Mitochondrial targeting compounds for the treatment of cancer and other disorders associated with mitochondrial function, including diabetes, autoimmune diseases, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases and their preparation. The present invention is also directed to the pharmaceutical compositions and treatment methods, prodrugs based on those compounds and the use thereof.

Abstract: An electronic device obtains structural data of a reference molecule. The electronic device performs structural separation on the structural data of the reference molecule to obtain group data of a molecular segment group corresponding to the reference molecule. The electronic device performs feature processing on the group data of the molecular segment group to obtain a candidate segment for replacing the fragment segment. The electronic device generates structural data of a reconstructed molecule based on the candidate segment and the side chain segment.

Abstract: Various embodiments include a testing apparatus capable of testing gas flowing in a duct. The apparatus may include: a housing; a sampling tube extending from the housing to be inserted into the duct, the sampling tube including a gas entry channel and a gas exit channel isolated from each other, with a gas inlet of the gas entry channel and a gas outlet of the gas exit channel disposed in a part of the sampling tube leading into the duct and disposed at the same side of the sampling tube, wherein the gas inlet and the gas outlet have matching gas through-flow areas; and a sensor module disposed in the housing and in gas communication with the gas entry channel to test gas sampled from the gas entry channel.

Abstract: A new on chip system, named Acoustic Gym, to apply a surface acoustic wave (SAW) has been developed to control the swimming exercise of a large number of small animals such as C. elegans and Zebra fish, at desired intensities and durations. The SAW device consists of a circular chamber filled with fluid, which is placed in the center between a pair of offset interdigital transducers (IDTs) that are deposited on a piezoelectric substrate. Upon actuation from a radio frequency (RF) source, the SAW is generated and propagates along the substrate towards the microchamber. Once the SAW reaches the chamber, it induces an acoustic streaming in the fluid inside the chamber to stimulate swimming exercise of small animals. The streaming velocity can be precisely controlled via the RF signal input power, thus regulating the duration and intensity of exercise of the animals.

Abstract: The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.

Abstract: The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.

Abstract: The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein.

Abstract: The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein.

Abstract: The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein.

Abstract: The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein.

Abstract: An assay uses apoptotic nucleases to screen for apoptosis modulators, in a method of modulating apoptosis, and in a method of aiding in a diagnosis of a disease, among other methods. materials for use in the assay include isolated or recombinant polypeptides and polynucleotides, compositions comprising those isolated or recombinant polypeptides and polynucleotides, vectors, transgenic organisms, and integrated systems among other aspects.

Abstract: An assay uses apoptotic nucleases to screen for apoptosis modulators, in a method of modulating apoptosis, and in a method of aiding in a diagnosis of a disease, among other methods. materials for use in the assay include isolated or recombinant polypeptides and polynucleotides, compositions comprising those isolated or recombinant polypeptides and polynucleotides, vectors, transgenic organisms, and integrated systems among other aspects.